Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)

NCT07472608 | Not Yet Recruiting

• 1 other identifier: 2025-4343
• Study Type: observational
• Target: 25,000
• Locations: 1 country
• Sites: 1

Brief Summary

Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications. A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body. This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:

1. 1.To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval
2. 2.To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity
3. 3.To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities
4. 4.To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and/or
5. 5.To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.

Conditions

Obesity; Metabolic Abnormalities; Health

Keywords

Biobank; Clinical data; Radiological data; Genetic data; Biochemical data; Cardiac data; Blood samples; Prospective patient registry; Bariatric medicine; Health; Obesity medicine

Outcome Measures

Primary Outcomes (1)

• Success or failure of obesity medicine interventions

  1. Anthropometric Parameters: weight and height combined to obtain BMI (kg/m\^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis 2. Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available) 3. Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts 4. Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts 5. Mental Health Parameters: As recorded in medical charts

  Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another

Study Arms (1)

Obesity medicine cohort

This cohort includes patients followed in bariatric medicine at IUCPQ-ULaval

Other: Behavioral and Pharmacological Treatments

Interventions

Behavioral and Pharmacological Treatments OTHER

Behavioral and pharmacological treatments are part of the standard of care and will vary among individuals based on their specific needs.

Obesity medicine cohort

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patient starting follow-up at the Bariatric Medicine Clinic of the IUCPQ-ULaval.

To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria: 1. Be over 18 years of age 2. Meet at least one of the following five criteria: 1. Body mass index ≥30 kg/m2 with or without comorbidities (preclinical or clinical obesity); 2. Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.); 3. History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost; 4. History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team; 5. Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Institut universitaire de cardiologie et de pneumologie de Québec, University Laval: lead
• Eli Lilly and Company: collaborator

Study Sites (1)

Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec

Québec, Quebec, G1V 4G5, Canada

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples.

MeSH Terms

Conditions

Obesity

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Therapeutics

Central Study Contacts

Audrey St-Laurent, PhD

CONTACT

418-656-8711; audrey.st-laurent@criucpq.ulaval.ca

Fannie Lajeunesse-Trempe, MD PhD FRCPC

CONTACT

418-656-8711; fanny.lajeunesse-trempe.1@ulaval.ca

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 25 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinician-Researcher

Study Record Dates

• First Submitted: February 27, 2026
• First Posted: March 16, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2051
• Study Completion (Estimated): June 1, 2051
• Last Updated: March 16, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)